Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Johan M. Spoor is Chief Executive Officer at Perspective Therapeutics. OQRO lists 7 transactions filed with the SEC under this name, the latest on Nov 12, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
7
Companies involved
1
3 buys, median −28.1 pts vs S&P 500, beat it 1 of 3 times.
Average −4.1 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 26, 2024 to Apr 1, 2025, measured from the first close after the filing. Past results, not a forecast.
4 purchases disclosed; 33% of the 3 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $1K today ($1K put in); the same in the S&P 500 (SPY): $1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Perspective TherapeuticsCATX
7 disclosures · Nov 2024 – Nov 2026 · 7 bought
Nov 11, 2026Bought~$38Kdisclosed Nov 12
DetailsOfficial recordMar 28, 2025Bought~$49Kdisclosed Apr 1
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Mar 28, 2025Bought~$10Kdisclosed Apr 1
DetailsOfficial recordDec 4, 2024Bought~$30K
DetailsOfficial recordNov 25, 2024Bought~$55Kdisclosed Nov 26
DetailsOfficial recordNov 25, 2024Bought~$25Kdisclosed Nov 26
DetailsOfficial recordNov 25, 2024Bought~$21Kdisclosed Nov 26
DetailsOfficial recordJohan M. Spoor bought shares on the open market in 2018, 2024, 2025 and 2026 across 2 companies.
Johan M. Spoor reported 9 open-market purchases and 0 sales since 2018; purchases in 4 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $38K1×1 trade | — |
| 2025 | $60K2×2 trades | — |
| 2024 | $248K5×5 trades | — |
| 2018 | $50K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Johan M. Spoor reported holding 183,033 shares of Perspective Therapeutics (CATX), worth about $173K at the last close of $1 (Nov 13, 2026): 106,383 held directly and 76,650 through a child #1, an ira of spouse, an ira of reporting owner. In the last 12 months, Johan M. Spoor bought $38K in 1 open-market purchase.
Perspective Therapeutics's proxy statement reports total compensation of $2.4M for Johan M. Spoor for fiscal year 2025, after $5.38M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 16, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Perspective Therapeutics CATX | 183,033 | 106K direct · 4,650 child #1 · 67K ira of spouse · 5,400 ira of reporting owner | $1 | $173K | Nov 11, 2026 |
Is this Johan M. Spoor’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with .
On the latest SEC Form 4, dated Nov 11, 2026, Johan M. Spoor reported holding 183,033 shares of Perspective Therapeutics (CATX), of which 76,650 are held indirectly. At the last close of $1 on Nov 13, 2026, that is about $173K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Johan M. Spoor reported 1 open-market purchase worth $38K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Perspective Therapeutics's proxy statement reports total compensation of $2.4M for Johan M. Spoor for fiscal year 2025, after $5.38M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Johan M. Spoor bought shares on the open market in 2018, 2024, 2025 and 2026 across 2 companies.
In SEC filings since 2018: the latest open-market purchase is from 2026; no open-market sale is on record.
2 companies: Perspective Therapeutics (CATX, 2024–2026), Gridai Technologies (GRDX, 2018).
Johan M. Spoor reported 8 open-market purchases and 0 sales here, 2024 to 2026.
Johan M. Spoor reported 1 open-market purchase and 0 sales here, 2018.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
